From Gila Monster Venom to Diabetes Drug: The Story of the Peptide Behind Exenatide | Research

The takeaway

This review traces how exendin-4, a 39-amino acid peptide from Gila monster venom, became the foundation for GLP-1 receptor agonist drugs used to treat type 2 diabetes, and explores its structure, mechanism, and ongoing improvements.

39-amino acid peptide from lizard venom
Exendin-4 from Gila monster venom became the first GLP-1 receptor agonist drug (exenatide/Byetta), founding a drug class that now includes semaglutide and tirzepatide

What the researchers found

Exendin-4, a 39-amino acid peptide discovered in Gila monster (Heloderma suspectum) venom, is a full agonist of the GLP-1 receptor with a longer half-life than endogenous GLP-1 due to resistance to DPP-4 enzymatic degradation. Its helical region interacts with the GLP-1 receptor's extracellular N-terminal domain while its C-terminal tryptophan cage enhances binding affinity, switching the receptor from auto-inhibited to auto-activated state. Beyond blood glucose lowering through enhanced β-cell function and GLP-1 receptor upregulation, exendin-4 has shown benefits for neuropathy, nephropathy, and ventricular remodeling. While it has reasonable subcutaneous bioavailability, its half-life remains relatively short, prompting ongoing modifications to improve pharmacokinetics and potency.

Why it matters

Exendin-4 is the natural peptide that gave rise to exenatide (Byetta), the first GLP-1 receptor agonist drug approved for type 2 diabetes. Its discovery from lizard venom is one of the most celebrated examples of venom-derived drug development and laid the foundation for the entire GLP-1 agonist drug class — now one of the most impactful classes of medications in modern medicine, including semaglutide (Ozempic/Wegovy).

The numbers in context

39 amino acids · Full GLP-1 receptor agonist · Longer half-life than endogenous GLP-1 · Benefits beyond glucose: neuropathy, nephropathy, cardiac remodeling

How the study worked

Narrative review covering the discovery, pharmacology, structure-function relationships, clinical trial evidence, and ongoing modifications of exendin-4 as a GLP-1 receptor agonist for type 2 diabetes treatment.

Who was studied

Review of exendin-4 pharmacology and its development as a type 2 diabetes treatment

What this study cannot tell us

As a narrative review, this paper synthesizes existing literature rather than presenting new data. The review was published in 2019, before the widespread clinical use of newer GLP-1 agonists like semaglutide and tirzepatide, so it does not cover the latest developments in the field.

How to read the evidence

This is a narrative review synthesizing decades of research on exendin-4's pharmacology and clinical development. While it does not present new primary data, it draws on a substantial body of preclinical and clinical evidence, including clinical trials of exenatide.

When this study was published

Published in 2019, this review covers the field up to that point. Since then, newer GLP-1 agonists like semaglutide and dual-agonist tirzepatide have advanced significantly, but exendin-4 remains the foundational molecule and the pharmacological principles described here are still relevant.

The bigger picture

Exendin-4's discovery launched the entire GLP-1 receptor agonist drug class, which now includes blockbuster medications like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro). The story exemplifies how studying animal venoms — a rich source of bioactive peptides — can lead to transformative medicines. The ongoing modifications to improve exendin-4's pharmacokinetics have directly informed the development of longer-acting and more potent GLP-1 agonists.

Questions still open

What structural modifications to exendin-4 have been most successful in extending its half-life and improving clinical outcomes?
Could exendin-4's neuroprotective and cardioprotective effects be developed into standalone treatments for neurodegenerative or cardiovascular diseases?
Are there other venom-derived peptides with similar potential for drug development that remain unexplored?

Common questions

How was a diabetes drug discovered in lizard venom?

In the early 1990s, researcher John Eng discovered that Gila monster venom contained a peptide called exendin-4 that strongly activates the GLP-1 receptor — the same receptor triggered by a human gut hormone that helps control blood sugar after meals. Unlike the human hormone, the lizard peptide resists enzymatic breakdown, making it last much longer in the body. This led to the development of exenatide (brand name Byetta), the first GLP-1 receptor agonist drug.

Is exendin-4 related to newer weight loss drugs like Ozempic?

Yes — exendin-4 and its drug form exenatide were the first GLP-1 receptor agonists, proving that this approach works for diabetes treatment. Semaglutide (Ozempic/Wegovy) and other newer drugs in the class were developed based on the same principle but with chemical modifications to last longer and work more potently. The discovery of exendin-4 in lizard venom essentially launched the entire GLP-1 drug revolution.

Read the original research

Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant.

Basic & clinical pharmacology & toxicology, 124(5), 513-527

View on PubMed ↗Publisher’s paper ↗

Citation

Yap, Michelle Khai Khun; Misuan, Nurhamimah. (2019). Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant.. Basic & clinical pharmacology & toxicology, 124(5), 513-527. https://doi.org/10.1111/bcpt.13169